Oral bropirimine immunotherapy of carcinoma in situ of the bladder: Results of a phase II trial

Urology

Volumn 48, Issue 1, 1996, Pages 21-27

  Sarosdy, Michael F ^b   Lowe, Bruce A ^c   Schellhammer, Paul F ^c   Lamm, Donald L ^c   Graham Jr , Sam D ^c   Grossman, H Barton ^a   See, William A ^c   Peabody, James O ^c   Moon, Timothy D ^c   Flanigan, Robert C ^c   Crawford, E David ^c   Morganroth, Joel ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BROPIRIMINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER TOXICITY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0343377307     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)90059-X     Document Type: Article

References (31)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 45:1995;8-30.
2. Surveillance, initial assessment, and subsequent progress of patients with superficial bladder cancer in a prospective longitudinal study. Cancer Res. 37:1977;2907-2910.
3. Farrow GM, Utz DC, Rife CC. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res. 36:1976;2495-2501.
4. Jewett HJ, Strong GH. Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol. 55:1946;366-372.
5. Althausen AF, Prout GR, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 116:1976;575-580.
6. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med. 322:1990;1129-1138.
7. Farrow GM, Utz DC, Rife CC, Greene LF. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res. 37:1977;2794-2798.
8. Sarosdy MF, Lamm DL. Long-term results of intravesical Bacillus Calmette-Guerin therapy for superficial bladder carcinoma. J Urol. 142:1989;719-722.
9. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209.
10. Morales A, Nickel JC, Wilson JWL. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol. 147:1992;1256-1258.
11. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 152:1994;367-373.
12. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 137:1987;220-224.
13. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF Jr, Fair WR, Oettgen HF. A prospective randomized trial of maintenance versus non-maintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 5:1987;441-449.
14. Brosman S. The influence of tice strain BCG treatment in patients with transitional cell carcinoma in situ. Prog Clin Biol Res. 310:1989;193-205.
15. Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna MG Jr, Pagano F, Alfthan O, Brosman S, Fisher HAF, Jakse G, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res. 310:1989;335-355.
16. Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT. Fatal sepsis following intravesical BCG administration for bladder cancer: a Southwest Oncology Group study. J Urol. 144:1990;1328-1330.
17. Lotzova E, Savary CA, Stringfellow DA. 5-halo-6-phenyl-pyrimidinones: new molecules with cancer chemotherapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells. J Immunol. 130:1983;965-969.
18. Lotzova E, Savary CA, Khan A, Stringfellow DA. Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone. J Immunol. 132:1984;2566-2570.
19. Wierenga W. Antiviral and other bioactivities of pyrimidinones. Pharmacol Ther. 30:1985;67-89.
20. Tracey DE, Richard KA. Mechanisms of immunostimulation by pyrimidinones. Prog Leukocyte Biol. 6:1987;279-289.
21. Sarosdy MF, Kierum CA. Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J Urol. 142:1989;1376-1379.
22. Sidky YA, Borden EC, Wierenga W, Bryan GT. Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors. Cancer Res. 46:1986;3798-3802.
23. Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol. 147:1992;31-33.
24. Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD Jr, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, et al. Bropirimine immunotherapy of bladder CIS: positive phase II results of an oral interferon inducer. Proc Annu Meet Am Soc Clin Oncol. 13:1994;A719.
25. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol. 14:1987;1-12. (suppl 2).
26. Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J, et al. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol. 6:1988;476-483.
27. Williams R, Sarosdy M, Catalona W, Chodak G, Vogelsang N, Freika F, Torti F. Randomized trial of high vs. low dose intravesical interferon alpha 2-B (IFN-α2β) treatment of bladder carcinoma in situ (CIS). Proc Am Soc Clin Oncol. 7:1988;121.
28. Simmons WB, Reichert DF, Lucio RM, Lamm DL. Pyrimidinone interferon inducers in the treatment of murine transitional cell carcinoma. Proceedings of the 78th Annual Meeting of the American Urological Association, Las Vegas, Nevada. 1983;169.
29. Kita M, Tong LJ, Imanishi J. Induction of IFN-α, IL-1β, and TNF-α mRNA by bropirimine in human bladder cancer cells. Igaku no Ayumi. 169:1994;307-308.
30. Li LH, Wallace TL, Hamilton RD, DeKoning TF. Relationship between activation of natural killer cell activity and antitumor activity of pyrimidinones. Schmidt RE. Natural Killer Cells: Biology and Clinical. 1990;248-253 Karger, Basel.
31. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, Koch MO, Schellhammer PF. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 48:1996;28-32.